EGFR and familial pancreatic carcinoma: In the present work, the pancreatic cancer cell lines BxPC-3 and PANC-1 were used, as well as primary human dermal fibroblasts (hNDF), as a control of healthy, non-tumor cells, to study the effect of the tyrosine kinase inhibitor (TKI) erlotinib on EGFR internalization and degradation in a three-dimensional (3D) environment.